Medtronic reported FY 2Q20 revenue of USD $828.7 million, +7.2% vs. FY 2Q19.

• Medtronic reported 6.7% organic growth for their Spine business (excluding $15 million from their Titan Spine acquisition, but including enabling technology reported in their Brain business)
• The company’s Surgical Synergy strategy, combining enabling technology, hardware and biologics into a single procedure, continues to be a growth driver
• Core spine products grew 3% organically, driven by penetration from new products like the T2 Stratosphere, Infinity OCT and Prestige LP systems
• Infuse bone graft experienced double-digit growth, aided by a one-time distributor startup order
• ORTHOWORLD projects Medtronic full calendar year 2019 orthopedic revenue of $3.4 billion, +6.5% vs. 2018

“The results in the spine business, which are the best we’ve seen in a long time, are the direct result of the Surgical Synergy strategy that has meaningfully improved the intrinsic value of our spine franchises. It’s the capital equipment, the Mazor O-Arm navigation, significant placements, sales and pull-through of the spine implants. This has created a great competitive differentiation and nice business model for us.” – Geoffrey Martha, EVP and President of Restorative Therapies Group

ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows.

ORTHOWORLD estimates orthopaedic sales by geographic region as follows.

Net earnings are as follows.

Unless otherwise noted, all revenue figures are reported in USD $ millions.

Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.